Franck Pourcine

Creteil, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Creteil, FR 
OverviewLocationsClinical Research

Overview

Franck Pourcine practices in Creteil, France. His top areas of expertise are Malignant Hypertension, Membranous Nephropathy, Membranoproliferative Glomerulonephritis, and Thrombocytopenia.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Creteil, France
Other Locations
Melun, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Comparison of Regional Citrate Anticoagulation (RCA) and Regional Anticoagulation by Citrate-Free Decalcification in Renal (RACD) Replacement Therapy Using Sustained Low-Efficiency Dialysis
Comparison of Regional Citrate Anticoagulation (RCA) and Regional Anticoagulation by Citrate-Free Decalcification in Renal (RACD) Replacement Therapy Using Sustained Low-Efficiency Dialysis
Enrollment Status: Recruiting
Publish Date: June 10, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

14 Total Publications

ATG-Fresenius increases the risk of red blood cell transfusion after kidney transplantation.
ATG-Fresenius increases the risk of red blood cell transfusion after kidney transplantation.
Journal: Frontiers in immunology
Published: September 15, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pourcine's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile